Immunitybio Inc (DE:26CA)
NASDAQ:26CA
26CA Stock Chart & Stats
€6.55
-€0.11(-4.34%)
At close: 4:00 PM EST
€6.55
-€0.11(-4.34%)
Day’s Range― - ―
52-Week Range€1.68 - €10.40
Previous CloseN/A
Volume0.00
Average Volume (3M)1.88K
Market Cap
€6.65B
Enterprise Value€8.24B
Total Cash (Recent Filing)€380.88M
Total Debt (Recent Filing)€1.12B
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Aug 12, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding1,047,354,000
10 Day Avg. Volume4,650
30 Day Avg. Volume1,875
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-3.65
Price to Sales (P/S)16.08
P/FCF Ratio-5.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.28Price Target Upside72.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.6
Revenue Forecast (FY)€181.65M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue & Gross MarginsA commercial-stage product (ANKTIVA) driving $141M TTM with ~94% gross margin indicates durable unit economics and a real revenue base. High gross margins provide operating leverage as sales scale and support reinvestment in commercialization and pipeline activities over coming quarters.
Strategic BCG Supply RightsSecuring exclusive U.S. development and supply rights to Tokyo-172 BCG for ten years materially strengthens the company’s positioning in bladder cancer care. It reduces chronic BCG shortage risk, complements ANKTIVA combination use, and improves long-term commercial reliability for providers and patients.
Balance Sheet Bolstered With Financing And ConversionThe $75M expansion of non-dilutive revenue financing and a $25M insider debt-to-equity conversion reduced immediate leverage and added committed capital. These moves enhance near-term liquidity for commercialization and limit near-term dilution while supporting continued roll-out of ANKTIVA.
Bears Say
Large Cumulative Losses & Negative EquityMassive accumulated losses and materially negative equity are structural concerns: they reflect prolonged unprofitability, reduce the company’s capital cushion, constrain borrowing capacity, and increase reliance on external financing or equity raises to fund operations over the medium term.
Persistent Negative Cash FlowSustained negative operating and free cash flow implies operations consume significant cash to support commercialization and R&D. Without a quick path to break-even, the company will repeatedly tap external financing, which can dilute shareholders or impose revenue-sharing obligations that compress long-term economics.
Regulatory/promotional Compliance RiskAn FDA Warning Letter over promotional communications creates lasting regulatory and reputational risk. It may restrict marketing practices, require costly compliance programs, and dampen prescriber confidence, which can slow commercial uptake of ANKTIVA and increase ongoing oversight costs for the company.
ImmunityBio News
26CA FAQ
What was Immunitybio Inc’s price range in the past 12 months?
Immunitybio Inc lowest stock price was €1.68 and its highest was €10.40 in the past 12 months.
What is Immunitybio Inc’s market cap?
Immunitybio Inc’s market cap is €6.65B.
When is Immunitybio Inc’s upcoming earnings report date?
Immunitybio Inc’s upcoming earnings report date is Aug 12, 2026 which is in 48 days.
How were Immunitybio Inc’s earnings last quarter?
Immunitybio Inc released its earnings results on May 07, 2026. The company reported -€0.545 earnings per share for the quarter, missing the consensus estimate of -€0.062 by -€0.483.
Is Immunitybio Inc overvalued?
According to Wall Street analysts Immunitybio Inc’s price is currently Undervalued.
Does Immunitybio Inc pay dividends?
Immunitybio Inc does not currently pay dividends.
What is Immunitybio Inc’s EPS estimate?
Immunitybio Inc’s EPS estimate is -0.08.
How many shares outstanding does Immunitybio Inc have?
Immunitybio Inc has 1,047,354,000 shares outstanding.
What happened to Immunitybio Inc’s price movement after its last earnings report?
Immunitybio Inc reported an EPS of -€0.545 in its last earnings report, missing expectations of -€0.062. Following the earnings report the stock price went down -7.082%.
Which hedge fund is a major shareholder of Immunitybio Inc?
Currently, no hedge funds are holding shares in DE:26CA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImmunityBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€11.28 (72.27% Upside)
€11.28 (72.27% Upside)
Blogger Sentiment
Bullish
DE:26CA Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €21.8M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
165.21%
12-Months-Change
Fundamentals
Return on Equity
138.69%
Trailing 12-Months
Asset Growth
112.88%
Trailing 12-Months
Company Description
Immunitybio Inc
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
26CA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong commercial traction for ANKTIVA with very large year-over-year revenue and unit growth, multiple regulatory milestones (including EU conditional authorization and Saudi first-in-world lung cancer approval), robust enrollment and promising clinical signals across randomized and single-arm QUILT programs, and strategic commercial partnerships and manufacturing initiatives. Offsetting these positives are substantial operating losses and cash burn, significant balance sheet liabilities, continued high R&D investment (including a one-time $14M equipment write-off), and some regulatory delays and market-access complexity in certain cohorts and geographies. Overall, the company is demonstrating clear commercial momentum and clinical progress but remains capital-intensive and faces execution and regulatory risks as it scales internationally.View all DE:26CA earnings summaries26CA Stock 12 Month Forecast
Average Price Target
€11.28
▲(72.27% Upside)
Technical Analysis
Catalyst Pharma
―
Immunovant
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Options Prices
Currently, No data available
---